EBMT 2024 | The recent FDA approval of ponatinib for Ph+ ALL following success in the PhALLCON trial
Alex Rampotas
• 16 Apr 2024
Alex Rampotas, MD, University College London, London, UK, shares his thoughts on the recent FDA approval of ponatinib for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dr Rampotas references the pivotal PhALLCON trial (NCT03589326), which found impressive overall survival (OS) following ponatinib treatment and led to the approval of this drug. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
